Literature DB >> 26920460

Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study.

Daniela Thorwarth1, Mike Notohamiprodjo2, Daniel Zips3, Arndt-Christan Müller3.   

Abstract

BACKGROUND: To increase tumour control probability (TCP) in prostate cancer a method was developed integrating multi-parametric functional and biological information into a dose painting treatment plan aiming focal dose-escalation to tumour sub-volumes. A dose-escalation map was derived considering individual, multi-parametric estimated tumour aggressiveness. METHODS AND MATERIALS: Multi-parametric functional imaging (MRI, Choline-/PSMA-/FMISO-PET/CT) was acquired for a high risk prostate cancer patient with a high level of tumour load (cT3b cN0 cM0) indicated by subtotal involvement of prostate including the right seminal vesicle and by PSA-level >100. Probability of tumour presence was determined by a combination of multi-parametric functional image information resulting in a voxel-based map of tumour aggressiveness. This probability map was directly integrated into dose optimization in order to plan for inhomogeneous, biological imaging based dose painting. Histograms of the multi-parametric prescription function were generated in addition to a differential histogram of the planned inhomogeneous doses. Comparison of prescribed doses with planned doses on a voxel level was realized using an effective DVH, containing the ratio of prescribed vs. planned dose for each tumour voxel.
RESULTS: Multi-parametric imaging data of PSMA, Choline and FMISO PET/CT as well as ADC maps derived from diffusion weighted MRI were combined to an individual probability map of tumour presence. Voxel-based prescription doses ranged from 75.3Gy up to 93.4Gy (median: 79.6Gy), whereas the planned dose painting doses varied only between 72.5 and 80.0Gy with a median dose of 75.7Gy. However, inhomogeneous voxel-based dose prescriptions can only be implemented into a treatment plan until a certain level.
CONCLUSION: Multi-parametric probability based dose painting in prostate cancer is technically and clinically feasible. However, detailed calibration functions to define the necessary probability functions need to be assessed in future clinical trials.
Copyright © 2016. Published by Elsevier GmbH.

Entities:  

Keywords:  Dose Painting; Multi-parametric imaging; Multi-parametrische Bildgebung; PET/MR; Prostatakarzinom; dose painting; functional imaging; funktionelle Bildgebung; prostate cancer

Mesh:

Year:  2016        PMID: 26920460     DOI: 10.1016/j.zemedi.2016.02.002

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  9 in total

Review 1.  Personalized radiotherapy treatment planning based on functional imaging.

Authors:  Malgorzata Skórska; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-15

2.  Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer.

Authors:  Marcel Nachbar; David Mönnich; Paul Kalwa; Daniel Zips; Daniela Thorwarth; Cihan Gani
Journal:  Strahlenther Onkol       Date:  2018-10-25       Impact factor: 3.621

3.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.

Authors:  Constantinos Zamboglou; Vanessa Drendel; Cordula A Jilg; Hans C Rischke; Teresa I Beck; Wolfgang Schultze-Seemann; Tobias Krauss; Michael Mix; Florian Schiller; Ulrich Wetterauer; Martin Werner; Mathias Langer; Michael Bock; Philipp T Meyer; Anca L Grosu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

4.  Dosimetric and Radiobiological Evaluation of Multiparametric MRI-Guided Dose Painting in Radiotherapy of Prostate Cancer.

Authors:  Iraj Abedi; Mohammad B Tavakkoli; Keyvan Jabbari; Alireza Amouheidari; Ghasem Yadegarfard
Journal:  J Med Signals Sens       Date:  2017 Apr-Jun

5.  Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI.

Authors:  E J Her; A Haworth; H M Reynolds; Y Sun; A Kennedy; V Panettieri; M Bangert; S Williams; M A Ebert
Journal:  Radiat Oncol       Date:  2020-07-13       Impact factor: 3.481

6.  An investigation of the conformity, feasibility, and expected clinical benefits of multiparametric MRI-guided dose painting radiotherapy in glioblastoma.

Authors:  Caterina Brighi; Paul J Keall; Lois C Holloway; Amy Walker; Brendan Whelan; Philip C de Witt Hamer; Niels Verburg; Farhannah Aly; Cathy Chen; Eng-Siew Koh; David E J Waddington
Journal:  Neurooncol Adv       Date:  2022-08-19

Review 7.  PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Authors:  Sebastian Zschaeck; Fabian Lohaus; Marcus Beck; Gregor Habl; Stephanie Kroeze; Constantinos Zamboglou; Stefan Alexander Koerber; Jürgen Debus; Tobias Hölscher; Peter Wust; Ute Ganswindt; Alexander D J Baur; Klaus Zöphel; Nikola Cihoric; Matthias Guckenberger; Stephanie E Combs; Anca Ligia Grosu; Pirus Ghadjar; Claus Belka
Journal:  Radiat Oncol       Date:  2018-05-11       Impact factor: 3.481

8.  Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.

Authors:  Stéphane Supiot; Caroline Rousseau; Mélanie Dore; Catherine Cheze-Le-Rest; Christine Kandel-Aznar; Vincent Potiron; Stéphane Guerif; François Paris; Ludovic Ferrer; Loïc Campion; Philippe Meingan; Gregory Delpon; Mathieu Hatt; Dimitris Visvikis
Journal:  Oncotarget       Date:  2018-01-13

Review 9.  Medical physics challenges in clinical MR-guided radiotherapy.

Authors:  Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi
Journal:  Radiat Oncol       Date:  2020-05-05       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.